Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Sep;35(9):1829–1833. doi: 10.1128/aac.35.9.1829

Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.

K V Clemons 1, D A Stevens 1
PMCID: PMC245276  PMID: 1952853

Abstract

The efficacy of a novel sterol-complexed preparation of amphotericin B, amphotericin B colloidal dispersion, was compared with that of deoxycholate-complexed amphotericin B in an acute murine model of systemic coccidioidomycosis. Mice (CD-1, female) were infected intravenously with 180 or 200 arthroconidia of Coccidioides immitis, and intravenous therapy was begun 3 days later. Six doses in various regimens of either preparation were given over 14 days, and deaths were tallied for an additional 35 days. All regimens that were not acutely lethal prolonged the survival of mice over that of controls (P less than 0.001). Quantitative determination of residual burdens of C. immitis in the spleen, liver, and lungs of survivors revealed that the colloidal dispersion was not as effective as the deoxycholate suspension on a milligram-per-kilogram basis. Deoxycholate suspension at 1.3 mg/kg cleared the organs in all mice, whereas colloidal dispersion at 5.0 mg/kg was the lowest dose that cleared organisms from all animals. Lower doses cleared organisms from fewer animals or cleared only selected organs. Deoxycholate suspension was more efficacious than colloidal dispersion in clearing C. immitis from the liver or lungs (P less than 0.05 to 0.01, dose and organ dependent) at identical doses. No overt toxicity was observed in mice treated with colloidal dispersion at 10 mg/kg. In contrast, deoxycholate suspension at 2.0 mg/kg was acutely toxic; 50% of the treated mice died after treatment. The two complexes were not equivalent on a milligram-per-kilogram basis; the deoxycholate suspension was three to four times more efficacious and also greater than 5- to greater than or equal to 8-fold more toxic. Thus, the therapeutic index of the colloidal dispersion complex is greater than that of the deoxycholate complex. The amount of amphotericin B per dose could also be increased when given as a colloidal dispersion to an optimally level. Amphotericin B colloidal dispersion shows promise for the therapy of disseminated coccidioidomycosis and should be tested in other animal models and in humans.

Full text

PDF
1829

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clemons K. V., Hanson L. H., Perlman A. M., Stevens D. A. Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis. Antimicrob Agents Chemother. 1990 May;34(5):928–930. doi: 10.1128/aac.34.5.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clemons K. V., Leathers C. R., Lee K. W. Systemic Coccidioides immitis infection in nude and beige mice. Infect Immun. 1985 Mar;47(3):814–821. doi: 10.1128/iai.47.3.814-821.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ellis W. G., Sobel R. A., Nielsen S. L. Leukoencephalopathy in patients treated with amphotericin B methyl ester. J Infect Dis. 1982 Aug;146(2):125–137. doi: 10.1093/infdis/146.2.125. [DOI] [PubMed] [Google Scholar]
  4. Graybill J. R., Craven P. C., Taylor R. L., Williams D. M., Magee W. E. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis. 1982 May;145(5):748–752. doi: 10.1093/infdis/145.2.748. [DOI] [PubMed] [Google Scholar]
  5. Graybill J. R., Kaster S. R. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis. 1984 Feb;129(2):292–295. [PubMed] [Google Scholar]
  6. Hoeprich P. Amphotericin B methyl ester and leukoencephalopathy: the other side of the coin. J Infect Dis. 1982 Aug;146(2):173–176. doi: 10.1093/infdis/146.2.173. [DOI] [PubMed] [Google Scholar]
  7. Hopfer R. L., Mills K., Mehta R., Lopez-Berestein G., Fainstein V., Juliano R. L. In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob Agents Chemother. 1984 Mar;25(3):387–389. doi: 10.1128/aac.25.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lawrence R. M., Hoeprich P. D. Comparison of amphotericin B and amphotericin B methyl ester: efficacy in murine coccidioidomycosis and toxicity. J Infect Dis. 1976 Feb;133(2):168–174. doi: 10.1093/infdis/133.2.168. [DOI] [PubMed] [Google Scholar]
  9. Lefler E., Brummer E., Perlman A. M., Stevens D. A. Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis. Antimicrob Agents Chemother. 1985 Mar;27(3):363–366. doi: 10.1128/aac.27.3.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lopez-Berestein G., Bodey G. P., Fainstein V., Keating M., Frankel L. S., Zeluff B., Gentry L., Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536. [PubMed] [Google Scholar]
  11. Lopez-Berestein G. Liposomes as carriers of antifungal drugs. Ann N Y Acad Sci. 1988;544:590–597. doi: 10.1111/j.1749-6632.1988.tb40459.x. [DOI] [PubMed] [Google Scholar]
  12. Morrison C. J., Stevens D. A. Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis. Antimicrob Agents Chemother. 1990 May;34(5):746–750. doi: 10.1128/aac.34.5.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Patterson T. F., Miniter P., Dijkstra J., Szoka F. C., Jr, Ryan J. L., Andriole V. T. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989 Apr;159(4):717–724. doi: 10.1093/infdis/159.4.717. [DOI] [PubMed] [Google Scholar]
  14. Shirkhoda A., Lopez-Berestein G., Holbert J. M., Luna M. A. Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology. 1986 May;159(2):349–353. doi: 10.1148/radiology.159.2.3961167. [DOI] [PubMed] [Google Scholar]
  15. Szoka F. C., Jr, Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987 Mar;31(3):421–429. doi: 10.1128/aac.31.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Taylor R. L., Williams D. M., Craven P. C., Graybill J. R., Drutz D. J., Magee W. E. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis. 1982 May;125(5):610–611. doi: 10.1164/arrd.1982.125.5.610. [DOI] [PubMed] [Google Scholar]
  17. Tremblay C., Barza M., Fiore C., Szoka F. Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1984 Aug;26(2):170–173. doi: 10.1128/aac.26.2.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Weber R. S., Lopez-Berestein G. Treatment of invasive Aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope. 1987 Aug;97(8 Pt 1):937–941. [PubMed] [Google Scholar]
  19. Wiebe V. J., DeGregorio M. W. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev Infect Dis. 1988 Nov-Dec;10(6):1097–1101. doi: 10.1093/clinids/10.6.1097. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES